Tatyana Kanzaveli

Big healthcare AI news yesterday as Tempus AI received the first-ever CPT code for an algorithm-only analysis of previously-sequenced, laboratory developed test transcriptomic data. TLDR: AI molecular phenotyping has a new business model. The PurISTSM test uses RNA profiling to identify molecular subtypes in patients with advanced pancreatic ductal adenocarcinoma, which may inform first-line therapy selection and management. While I'm skeptical that payer balance sheets are going to solve the "who pays for healthcare AI" problem, the reimbursement pipes for clinical AI are maturing. I am surprised to see more progress for usage-based vs. performance-based models given the many challenges with FFS economics. It will be interesting to see how payers assess the "medical necessity" and therefore reimbursability of clinical AI as these models come to market. https://t.co/eLe18SmihV

420

9 Comments

https://lnkd.in/d9jBs6Wg Join us next Wednesday July 10th at 16:30 – 17:30 UAE for the first webinar of the series. FROM BIG DATA TO BEDSIDE: IS AI REVOLUTIONIZING CANCER TREATMENT?

5

𝐀𝐈 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧: 𝐅𝐢𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐢𝐠𝐡𝐭 𝐁𝐚𝐥𝐚𝐧𝐜𝐞 Governor Gavin Newsom has just vetoed the SB 1047 AI safety bill, a move that’s sure to stir up the tech world in California. What does this mean for the future of AI innovation and safety? Let’s break it down. 1️⃣ 𝑻𝒉𝒆 𝑺𝑩 1047 𝑩𝒊𝒍𝒍 This bill wanted to add stricter safety measures for large AI models, even including “kill switches” to stop potential misuse. Sounds like a good idea, right? 2️⃣ 𝑾𝒉𝒚 𝑵𝒆𝒘𝒔𝒐𝒎 𝑽𝒆𝒕𝒐𝒆𝒅 𝑰𝒕 Newsom thinks the bill was too broad. It only focused on big AI models, which he believes might give people a false sense of security. Are we overlooking the smaller, equally risky models? 3️⃣ 𝑯𝒊𝒔 𝑽𝒊𝒔𝒊𝒐𝒏 𝒇𝒐𝒓 𝑨𝑰 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒊𝒐𝒏 Instead of blanket regulations, he’s pushing for a more targeted approach—one that addresses real risks without slowing down the incredible innovation happening in California. 4️⃣ 𝑹𝒆𝒂𝒄𝒕𝒊𝒐𝒏𝒔 Supporters like tech leaders Yann LeCun (Meta) and Marc Andreessen (VC) are celebrating the veto as a win for progress. Critics like Senator Scott Weiner, who authored the bill, are concerned. They argue that powerful AI technologies are left with little oversight. Is that a valid worry? 5️⃣ 𝑻𝒉𝒆 𝑩𝒊𝒈 𝑸𝒖𝒆𝒔𝒕𝒊𝒐𝒏 Is this the right move for encouraging innovation, or a missed chance to make AI safer? 🤔 What do you think? 🔍 Should AI regulation focus on specific risks? Or do we need broader rules to keep the technology safe? Join the conversation! Drop your thoughts in the comments below👇 #AI #ArtificialIntelligence #Innovation #Technology #Regulation #California #AIsafety #TechLeadership

18

2 Comments

ArteraAI receives TIME's 2024 Best Invention Award, for the creation of our multi-modal AI (MMAI) platform that can personalize treatment for cancer patients. This is a true honor, and a testament to our work and commitment to advance accessible cancer care through novel AI methods. When you’re treating cancer, you’re trying to predict if a patient's future is better on one therapy or another, and that’s really difficult. It turns out AI is spectacular at it. Our #MMAI has been listed in the National Comprehensive Cancer Network® (NCCN®)'s guidelines for the treatment of prostate cancer, the official standard of care for oncology. It is reimbursed by Medicare, and it is broadly accessible across the US and certain ex-US geographies. Many thanks to our great investors for making this possible, but most importantly to an incredible team of #Arterans that hustle day in and day out to support patients globally. (It's such a privilege to be listed alongside Google DeepMind's AlphaFold3, and similar!) cc: Marc Benioff, Jim Breyer, Lip-Bu Tan, Abhishek Shukla, Navin Chaddha, Joy Shu Fen Ho, Nancy Ondovik, Chris Re, Amarjit Gill, Jeff Dean, Steve Blank, Andy Jacques, Dennis Wong, Clarence S., Michael Driscoll, Rajiv K., Andrew Tan, Elliott Tan, Walden Catalyst Ventures, Coatue, Koch Disruptive Technologies, Johnson & Johnson, FactoryVC, EDBI Pte Ltd, Prosperity7 Ventures, Breyer Capital, American Cancer Society

268

32 Comments

🌟 BREAKTHROUGH DISCOVERY IN CANCER GENETICS 🌟 UCLA researchers have published a groundbreaking study in Nature Communications that revolutionizes our understanding of how noncoding DNA influences cancer progression. Their discovery of mutations in these "silent" regions significantly impacting mRNA levels, leading to abnormal protein production which can accelerate or hinder cell proliferation, challenges previous assumptions about noncoding DNA's role. The study also introduces a new prognostic tool, the untranslated tumor mutation burden (uTMB), which could predict patient survival in certain cancers. This pioneering research paves the way for developing targeted treatments and personalized medicine strategies, offering new hope in the fight against cancer. #CancerResearch #Genetics #InnovativeScience

16